Skip to content

Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness

Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness: A Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02972411
Enrollment
30
Registered
2016-11-23
Start date
2016-10-31
Completion date
2017-05-31
Last updated
2016-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Altitude Sickness

Brief summary

This study evaluates the safety and efficacy of the voluntary ventilatory response as prophylaxis for acute mountain sickness, measured by the Lake Louise Self-Report Score, comparing to a group using acetazolamide.

Detailed description

Rationale: Acute mountain sickness (AMS) is a common condition among people who go to altitude and stay at altitude. Acclimatization is the most important mechanism in order to reduce the risk of AMS, however, this is not possible or adequate in a large part of the cases. Recently, there are indications that adjustment of respiration by means of a voluntary increase in the respiratory minute volume can have a similar prophylactic effect. The purpose of this study is to measure the effect of the voluntary increase of the minute volume by means of controlled hyperventilation as prophylaxis for acute mountain sickness without prior acclimatization, with AMS being expressed in the Lake Louise Self-Report Score (LLSRS). Objective: To investigate the safety and efficacy of the voluntary increase in minute ventilation by means of controlled hyperventilation as prophylaxis for AMS, measured by the LLSRS in a randomized controlled trial ascending to 4954m altitude. Study design: Prospective randomized controlled trial, safety and efficacy. Study population: 30 healthy subjects Intervention: The investigational prophylaxis is controlled hyperventilation. Participants in the interventional group will be trained to hyperventilate in a controlled fashion doing a series of exercises during the 4 days prior to the ascent. They will also be taught in a practical way to recognize early clinical signs and symptoms of hypocapnia. Main study parameters/endpoints: Safety and efficacy measured by comparing the LLSRS between the two groups. Target end-tidal CO2 ( PETCO2) will be measured to objectify adequate hyperventilation. Symptoms of hypocapnia due to the (pre-)intervention as well as any adverse events will be reported and analysed.

Interventions

BEHAVIORALVoluntary ventilatory response

Training of the subjects for voluntary increase in the respiratory minute ventilation

DRUGAcetazolamide

Acetazolamide 125mg. PO every 12 hours since 24 hours before ascent, until 48 hours at high altitude

Sponsors

Hospital del Trabajador de Santiago
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Living at lower altitude than 900 meters

Exclusion criteria

* Cardiac or pulmonary comorbidity * Smoking * Infectious disease during the last 30 days * BMI\> 30 * Pharmaceutical use as diuretics, corticosteroids, acetazolamide, or anti -inflammatory drugs during the 2 weeks prior to the study * A history of high altitude cerebral edema or high altitude pulmonary edema * Cardiovascular risk factors such as a personal history of cardiovascular disease, familial history of major adverse cardiovascular events (MACE) at age younger than 45 yrs, hypercholesterolemia and stroke.

Design outcomes

Primary

MeasureTime frameDescription
Lake Louise ScoreUp to 5 monthsIntensity and prevalence of Acute Mountain Sickness. During Ascent.

Secondary

MeasureTime frameDescription
Pulse oxygen saturationUp to 5 monthsDuring ascent.
Respiratory rateUp to 5 monthsDuring ascent
Heart rateUp to 5 monthsDuring ascent
Borg ScaleUp to 5 monthsDuring ascent
PETCO2Up to 5 monthsPressure of expired CO2, measured with a monitor in the moutain. During ascent.

Other

MeasureTime frameDescription
Training satisfactory after Ascent. PETCO2 below 20mmHgUp to 6 monthsAfter ascent.
Training satisfactory. PETCO2 below 20 mmHgUp to 6 monthsAfter ascent.
hypoxic ventilatory responseUp to 6 monthsBefore ascent

Countries

Chile

Contacts

Primary ContactSebastián Drago, MD
sebadrago@gmail.com+56992191310
Backup ContactJuan Campodónico, MD
campodonicouc@gmail.com+56981379351

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026